France· FR:63848228
CYRAMZA 10 mg/ml, solution à diluer pour perfusion
A medicinal product containing ramucirumab, registered in France by ELI LILLY (PAYS BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RAMUCIRUMAB
- Manufacturer
- ELI LILLY (PAYS BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009550002731 flacon(s) en verre de 10 ml
- cip1334009550002971 flacon(s) en verre de 50 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ramucirumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsCyramza 10 mg/ml, concentraat voor oplossing voor infusieEli Lilly Nederland BV
- SpainCYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONEli Lilly Nederland B.V.
- United StatesCYRAMZAEli Lilly and Company
- United KingdomCyramza 100mg/10ml concentrate for solution for infusion vialsOriginalis B.V.
- CzechiaCYRAMZAEli Lilly Nederland B.V., Utrecht
- BelgiumCyramza 10 mg/mlEli Lilly Nederland
- SwitzerlandCyramza
- FinlandCyramzaEli Lilly Nederland B.V
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cyramza
- Liechtenstein · Cyramza
- Norway · Cyramza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5a2e3474-02df-43ed-96d9-137e8e62ca29 GET /v1/drugs/5a2e3474-02df-43ed-96d9-137e8e62ca29?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63848228",
"date_amm": "2014-12-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/957",
"substance": "RAMUCIRUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ramucirumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.